PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Cited by 9 Publications

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

5 Customer Reviews

(F) EGR-2 and GFI-1 abundance (n = 5).

Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.
C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.
After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	M1;3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXJTWM2OD1yLkiyNFI1KM7:TR?=	M1j0SHNCVkeHUh?=
UACC-893	M3;qT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PoSGlEPTB;NT6xPVg5PiEQvF2=	M{X5ZXNCVkeHUh?=
A427	M17Ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnCe3hKSzVyPUWuO\|I2PjdizszN	MUfTRW5ITVJ?
OCUB-M	NXnDfldyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTZwNk[xNFIh\|ryP	MWPTRW5ITVJ?
SW684	NIfSVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjIcWlKSzVyPUeuOVIzPjhizszN	Moq5V2FPT0WU
SK-LMS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnySolKSzVyPUmuNFE{ODJizszN	NVzu[YtrW0GQR1XS
CP50-MEL-B	MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTlwM{C0NVkh\|ryP	MofPV2FPT0WU
NCI-H1651	M{XxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mle3TWM2OD1zMD6wNlc3KM7:TR?=	Mk\3V2FPT0WU
ABC-1	Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Lv[GlEPTB;MUCuNVA{PyEQvF2=	MVzTRW5ITVJ?
OE19	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPSTWM2OD1zMD6xO\|M{KM7:TR?=	MVvTRW5ITVJ?
DSH1	Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTFyLki4O\|kh\|ryP	NUL0RmZlW0GQR1XS
SW13	NVr2bItkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;pXWlEPTB;MUGuPVMyQSEQvF2=	M4DT[3NCVkeHUh?=
MDA-MB-453	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTF{LkG2NFMh\|ryP	NFzUOYVUSU6JRWK=
647-V	NWnD[4ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjBTGFLUUN3ME2xNk4{PTh{IN88US=>	Mn7YV2FPT0WU
NCI-H2342	M17p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFf1UYJKSzVyPUGyMlM6QTVizszN	MVHTRW5ITVJ?
LB2241-RCC	NGj4dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvaWYFRUUN3ME2xNk42Pzd7IN88US=>	MlPTV2FPT0WU
UACC-257	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTF\|LkS0OVMh\|ryP	M33aNnNCVkeHUh?=
NCI-H661	MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PBZWlEPTB;MUOuOlQ1QSEQvF2=	MojVV2FPT0WU
FADU	NX36OXBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTF\|Lk[5PVIh\|ryP	NYqycVlLW0GQR1XS
A2780	NVrWN5hXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHPTWM2OD1zMz64NFQyKM7:TR?=	M1TNfXNCVkeHUh?=
NCI-H1793	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTF2LkSwPFUh\|ryP	MoXNV2FPT0WU
TE-8	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLlPGNKSzVyPUG1MlM1PjVizszN	MmT6V2FPT0WU
HGC-27	MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPKTWM2OD1zNj6xOlQ1KM7:TR?=	NXK4PVlsW0GQR1XS
MMAC-SF	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1X0NmlEPTB;MUeuN\|czPyEQvF2=	M{fIfHNCVkeHUh?=
Calu-6	Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE[4bHVKSzVyPUG4MlE2OTNizszN	M3vKSHNCVkeHUh?=
HUTU-80	M3nVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHZUnB6UUN3ME2xPE4{QTV7IN88US=>	M1nuT3NCVkeHUh?=
SAS	NYe2cJhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jyfGlEPTB;MUiuOlQ2PSEQvF2=	MXzTRW5ITVJ?
IST-MES1	M2rH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTF6Lk[1NFgh\|ryP	Ml7IV2FPT0WU
C3A	NGHlTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrKUItCUUN3ME2xPE44QTF7IN88US=>	NGLsW4NUSU6JRWK=
ES3	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLySZdKSzVyPUG4Mlg{PjRizszN	MlvpV2FPT0WU
HSC-2	MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnDUlR4UUN3ME2xPU43PTRzIN88US=>	M{LofXNCVkeHUh?=
T47D	NXfu[INMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\sTWM2OD1{MD6xOFg2KM7:TR?=	MliwV2FPT0WU
EW-7	M4DOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlWwTWM2OD1{MD64OVg5KM7:TR?=	M4\MNnNCVkeHUh?=
LN-405	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEf6XFFKSzVyPUKwMlg6PjVizszN	MnHIV2FPT0WU
U031	MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFL1XIxKSzVyPUKxMlQ5ODJizszN	NGTj[WJUSU6JRWK=
A549	MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvCXWZKSzVyPUKxMlg1QTFizszN	MkeyV2FPT0WU
RMG-I	Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLhTWM2OD1{Mj6yOlY5KM7:TR?=	M1jMVHNCVkeHUh?=
BT-474	NXTkUJBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmL3TWM2OD1{Mj62OVUyKM7:TR?=	M3XWPXNCVkeHUh?=
NB69	M3myVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTtTWM2OD1{Mz6xOVIh\|ryP	MkO2V2FPT0WU
NB7	M{K0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XmXWlEPTB;MkSuNVg5KM7:TR?=	MWTTRW5ITVJ?
HCC1569	NYX1[FZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJ2Lk[xNlUh\|ryP	NX\oOWpOW0GQR1XS
MEL-JUSO	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTwSYU4UUN3ME2yOE43QTB6IN88US=>	MVfTRW5ITVJ?
MDA-MB-175-VII	M1L6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TDS2lEPTB;MkWuNlUyPyEQvF2=	NFHQR2tUSU6JRWK=
HCC1419	NXHS[opwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfaSFNKSzVyPUK1MlYxODNizszN	MlHuV2FPT0WU
Ca9-22	NWnCNZc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnCOG17UUN3ME2yOU43PDN{IN88US=>	M4nNZXNCVkeHUh?=
KGN	MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjLS4tSUUN3ME2yOU44PTR5IN88US=>	NGLHeXJUSU6JRWK=
LB373-MEL-D	NIHLV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJ4LkG5N\|gh\|ryP	NUjZTYtDW0GQR1XS
NCI-H1755	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTJ4Lki4OFEh\|ryP	M3vqPHNCVkeHUh?=
D-423MG	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLEXmhFUUN3ME2yO{4xPzF3IN88US=>	NWfBPVM5W0GQR1XS
DK-MG	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTJ6Lke4OFYh\|ryP	MnLZV2FPT0WU
NCI-H1623	M1;2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vOZmlEPTB;MkiuPFM1OiEQvF2=	NXLIcFc2W0GQR1XS
KU-19-19	NIXwZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3zTWM2OD1{OD65PVUh\|ryP	MXnTRW5ITVJ?
C-33-A	MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TNRmlEPTB;MkmuNlE6QCEQvF2=	Mn72V2FPT0WU
SCC-4	MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfCOnlpUUN3ME2zNE4{OzV2IN88US=>	MkW2V2FPT0WU
MG-63	NWPacFVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37odWlEPTB;M{CuOVk6PCEQvF2=	MmOzV2FPT0WU
LNCaP-Clone-FGC	M{H5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[wfJRlUUN3ME2zNU41QTJzIN88US=>	NITZe5pUSU6JRWK=
CAPAN-1	NVLMcno3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIC4RpJKSzVyPUOxMlUzQDZizszN	M{TCcnNCVkeHUh?=
GI-ME-N	M{S2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETQSZpKSzVyPUOxMlU{PTNizszN	NIe5XYJUSU6JRWK=
RERF-LC-MS	NG[4Xo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTN{Lk[3OFch\|ryP	NXX6WmJMW0GQR1XS
KLE	NWG2eINYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTZTWM2OD1\|Mz60N\|M1KM7:TR?=	NEjzTpFUSU6JRWK=
KNS-81-FD	NWjkT3NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYX6cW1NUUN3ME2zN{42ODB6IN88US=>	MWfTRW5ITVJ?
DOK	NVT5cIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV6yc\|NOUUN3ME2zOE43PjF{IN88US=>	NXX3fpM4W0GQR1XS
ACHN	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3uTWM2OD1\|NT6xOVg5KM7:TR?=	M4rnbHNCVkeHUh?=
KYSE-520	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnkO3RKUUN3ME2zOU4zOzZzIN88US=>	NIWyPHlUSU6JRWK=
SBC-5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\F[mlEPTB;M{WuOVEyPiEQvF2=	MYDTRW5ITVJ?
NCI-H28	MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHKR3huUUN3ME2zOU43Pjl3IN88US=>	NVzrdohFW0GQR1XS
ES7	Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTN4LkKyOFkh\|ryP	NYrmT4ZYW0GQR1XS
A172	NUjPfG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrXTWM2OD1\|Nj60NVg4KM7:TR?=	Ml3WV2FPT0WU
UM-UC-3	M2HSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzsTWM2OD1\|Nz64O\|Q3KM7:TR?=	M{PiUHNCVkeHUh?=
LXF-289	MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTrcmRKSzVyPUO4MlAxPDdizszN	MkjIV2FPT0WU
KP-4	M33GNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;oZoFRUUN3ME2zPE41PzN7IN88US=>	NX3RS2pNW0GQR1XS
TE-1	NWPHfG16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVv3OlR1UUN3ME2zPU43PTh7IN88US=>	MojhV2FPT0WU
G-402	NGjSVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLUWZV6UUN3ME20NE4xPjFizszN	M4PxfHNCVkeHUh?=
786-0	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjnXGFKSzVyPUSwMlkxQTZizszN	M1nrfnNCVkeHUh?=
K5	MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTRzLkO2PFYh\|ryP	NILCXFRUSU6JRWK=
SK-N-DZ	NI\sOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHmcnhMUUN3ME20NU4{QDJ\|IN88US=>	NYrM[G0zW0GQR1XS
OVCAR-4	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Thc2lEPTB;NEGuO\|U3QCEQvF2=	NHzpbHZUSU6JRWK=
T84	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTR{LkGyOlMh\|ryP	MkTyV2FPT0WU
GCIY	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXO[IcyUUN3ME20N{4xQDB\|IN88US=>	M2XBfnNCVkeHUh?=
BB49-HNC	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fMfGlEPTB;NEOuN\|M1QCEQvF2=	MYjTRW5ITVJ?
SNU-C2B	M2DzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHVUI9KSzVyPUSzMlY1OzZizszN	NIrEc\|ZUSU6JRWK=
TE-6	NUKyWVZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DtOmlEPTB;NEOuPFg6PCEQvF2=	NGrDPJRUSU6JRWK=
23132-87	NU\iPVFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4G5fWlEPTB;NESuNlk4QCEQvF2=	MmSwV2FPT0WU
DMS-53	M{HsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2D6SmlEPTB;NESuN\|M5PCEQvF2=	MkCyV2FPT0WU
ONS-76	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmK4TWM2OD12ND63OlYyKM7:TR?=	NH3NdINUSU6JRWK=
DMS-273	NF;4XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnoNXdEUUN3ME20OE46PDNizszN	MmHIV2FPT0WU
COLO-824	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTR3Lki3O\|Uh\|ryP	NIP6XHNUSU6JRWK=
DMS-114	NWDLcZI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\UXmJKSzVyPUS1Mlg6OjdizszN	NUPOeGtlW0GQR1XS
YKG-1	M{TiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml21TWM2OD12Nj6wN\|U2KM7:TR?=	MYnTRW5ITVJ?
RH-18	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLJTWM2OD12Nj6zO\|M{KM7:TR?=	Mn3mV2FPT0WU
NCI-H1355	NV3Fe4VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIi2[YJKSzVyPUS2MlYyQCEQvF2=	MU\TRW5ITVJ?
NCI-H2170	M1fDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTR5Lke1PFQh\|ryP	MYrTRW5ITVJ?
OC-314	NFHVcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LpV2lEPTB;NEeuPFQ4QCEQvF2=	M{PqXXNCVkeHUh?=
NCI-H2030	M2nYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTR5Lki5NFYh\|ryP	M2nkcXNCVkeHUh?=
22RV1	M2jkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHJN\|Q5UUN3ME20O{46ODF3IN88US=>	NEPnT5pUSU6JRWK=
G-401	Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkWwTWM2OD12OD60OFE2KM7:TR?=	NUS0T\|BRW0GQR1XS
YAPC	NVrDUo1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LZPGlEPTB;NEmuPFA4OyEQvF2=	MofvV2FPT0WU
SW1573	NUOzd5BMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PWVmlEPTB;NUCuNlQ{PSEQvF2=	NYDlU3VKW0GQR1XS
COLO-792	NU[wVGVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[yVmlEPTB;NUCuOlI{PyEQvF2=	M4TDeHNCVkeHUh?=
KNS-62	NHvGSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXaTWM2OD13MD63OVA5KM7:TR?=	NF7EOJZUSU6JRWK=
NB5	MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF23fWJKSzVyPUWxMlQ2ODlizszN	MUnTRW5ITVJ?
CP66-MEL	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTVzLk[0NFgh\|ryP	M1LQc3NCVkeHUh?=
CaR-1	NETubnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\Qe2lEPTB;NUKuNFYxPiEQvF2=	NIDrfYtUSU6JRWK=
CAL-54	NFrsfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF6zRYdKSzVyPUWyMlEyODJizszN	NIXCcZJUSU6JRWK=
8305C	M3XF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7DdWFUUUN3ME21Nk4{OTVizszN	MVLTRW5ITVJ?
Calu-3	NFK4NGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\GTWM2OD13Mj6zO\|M{KM7:TR?=	MVvTRW5ITVJ?
AU565	NGDKfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTvNmZKSzVyPUWyMlU2ODlizszN	M1q2O3NCVkeHUh?=
CW-2	NWPkdYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zqPWlEPTB;NUKuPFY2PCEQvF2=	NGn1Z41USU6JRWK=
BEN	NHTMV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFToVolKSzVyPUWzMlc5PjJizszN	M1PBPHNCVkeHUh?=
NCI-H1975	M4nhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PmSmlEPTB;NUOuPFk3PiEQvF2=	Mnr6V2FPT0WU
HCT-116	MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzqXolKSzVyPUW0MlA{OjdizszN	NWTZNZJCW0GQR1XS
SH-4	M1zPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHNVYQyUUN3ME21OE4yOzhizszN	NWnuSZV3W0GQR1XS
NCI-H1693	NFvS[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmq0TWM2OD13ND6yNVA{KM7:TR?=	M{KydXNCVkeHUh?=
BPH-1	NIrnSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTQUZp7UUN3ME21OU4zQDl{IN88US=>	NYPUWZB2W0GQR1XS
CAMA-1	M1fGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmL3TWM2OD13NT64NVE3KM7:TR?=	M1iwPXNCVkeHUh?=
A388	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTqNFhKSzVyPUW2MlA6QDVizszN	MnrFV2FPT0WU
C2BBe1	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PpNmlEPTB;NU[uNlY{PCEQvF2=	NGKycmlUSU6JRWK=
GAMG	NF3iRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjqXlRKSzVyPUW2MlU6PTVizszN	MnTSV2FPT0WU
MKN28	NGLMe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTV4LkiwNVMh\|ryP	NGqyUFNUSU6JRWK=
VA-ES-BJ	MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTaZYpKSzVyPUW2Mlg4PDVizszN	MXLTRW5ITVJ?
HuCCT1	M4WxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;JSnZKSzVyPUW3MlA1QTJizszN	NVrvOXFxW0GQR1XS
BFTC-905	NFfhfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnmTWM2OD13Nz6yPFk5KM7:TR?=	MYPTRW5ITVJ?
LS-123	Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTV5LkW2Olgh\|ryP	M{nUSXNCVkeHUh?=
LB996-RCC	NGH5Zo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTV6LkCyPFch\|ryP	M3HNcXNCVkeHUh?=
NCI-H1048	NIfPO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXxTWM2OD13OD6yNVg5KM7:TR?=	M2e4WXNCVkeHUh?=
COR-L105	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Kzb2lEPTB;NUiuO\|M{PyEQvF2=	M3\WeHNCVkeHUh?=
OVCAR-8	NV;ONI5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfDR2xKSzVyPUW5MlE4OTZizszN	NWTkfZdFW0GQR1XS
SK-N-FI	NFPVb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTMSHFNUUN3ME21PU4{OjB5IN88US=>	MYjTRW5ITVJ?
MES-SA	NEHJNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTV7LkS1NFkh\|ryP	MUjTRW5ITVJ?
SCC-9	M1\vOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorDTWM2OD13OT60O\|U{KM7:TR?=	MlW5V2FPT0WU
EFO-27	MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUS4TlI5UUN3ME21PU46PDNizszN	MlS4V2FPT0WU
GT3TKB	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPq[FNKSzVyPU[wMlYxPDhizszN	NEjiVXhUSU6JRWK=
HCC38	M1jzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfaTWM2OD14MT60N\|c6KM7:TR?=	MlrBV2FPT0WU
MLMA	M2nIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LYUmlEPTB;NkGuOlE3OyEQvF2=	M1TkVnNCVkeHUh?=
D-566MG	NHywOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTZ\|LkWyNlQh\|ryP	MXrTRW5ITVJ?
SF295	M3PGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTZ\|Lk[2OVUh\|ryP	MWDTRW5ITVJ?
ES4	NV;Vb\|NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVf2b5ByUUN3ME22OE41PzF7IN88US=>	NHT6T5FUSU6JRWK=
CAKI-1	M2HXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTZ2LkW3NlEh\|ryP	NVHOTHd5W0GQR1XS
OAW-28	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTZ2Lkm2OFch\|ryP	NWHHVVZXW0GQR1XS
NCI-H460	MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfCTWM2OD14NT6wPFk4KM7:TR?=	NVzTUlNlW0GQR1XS
JAR	NHTZVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnftTWM2OD14NT61OVE3KM7:TR?=	MU\TRW5ITVJ?
SNU-449	M2i4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;lVlE2UUN3ME22OU44PjF4IN88US=>	NVrGe4pZW0GQR1XS
D-392MG	NFrMU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPZeJBVUUN3ME22OU46PDN2IN88US=>	NVTpbI5CW0GQR1XS
EW-22	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;OTWM2OD14Nj6zPVUh\|ryP	M2DTXXNCVkeHUh?=
GCT	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXodYhKSzVyPU[3MlA1PDNizszN	NXzFdG5uW0GQR1XS
NOS-1	M3jxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTZ5Lk[4Olch\|ryP	NIq4dGtUSU6JRWK=
RH-1	NVS2dINYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjRR2tKSzVyPU[4MlU2PTlizszN	MlrvV2FPT0WU
HuH-7	NIXDdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTZ7LkGwNFIh\|ryP	MoXEV2FPT0WU
NUGC-3	NEXlTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2T6S2lEPTB;N{CuPVY1PCEQvF2=	NV7rb4JkW0GQR1XS
IST-SL1	MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTNVY1UUUN3ME23NU4zOzJ2IN88US=>	M2XtR3NCVkeHUh?=
SHP-77	Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLOWohKSzVyPUeyMlEyQSEQvF2=	NYjQUXVjW0GQR1XS
SW1116	NEGwZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLMTWM2OD15Mj6xOFA4KM7:TR?=	NHjSR5pUSU6JRWK=
LK-2	MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTd{Lki2NVIh\|ryP	MW\TRW5ITVJ?
U-2-OS	M4rZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTd\|LkG4Nlgh\|ryP	M2Pze3NCVkeHUh?=
KYSE-150	NViwSZlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTTWmV5UUN3ME23N{43OTF6IN88US=>	NEnHd29USU6JRWK=
U251	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTWe2NKSzVyPUezMlgyPjhizszN	MkjoV2FPT0WU
HT-1080	NV7BNJZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTWNVZiUUN3ME23OE4zPTd2IN88US=>	MXHTRW5ITVJ?
NCI-H1437	NHW0R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDvTWM2OD15ND62N\|I3KM7:TR?=	M2HMVHNCVkeHUh?=
HPAF-II	NXnHSW1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTd2Lk[0NVUh\|ryP	NYrWUFdiW0GQR1XS
Becker	MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrPbmt4UUN3ME23OU4yOTB3IN88US=>	NFjjNlJUSU6JRWK=
PANC-10-05	M1rt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzBT29KSzVyPUe1MlI5PjVizszN	MWHTRW5ITVJ?
TYK-nu	Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fhUWlEPTB;N{WuN\|ExOiEQvF2=	M1PzXXNCVkeHUh?=
SKG-IIIa	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnv1TWM2OD15NT6zN\|QyKM7:TR?=	MmjGV2FPT0WU
NCI-H1993	NX;WTI8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHjfoFKSzVyPUe1Mlc{QTdizszN	NF;hNnlUSU6JRWK=
S-117	M2C3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:4TWM2OD15NT63OVUh\|ryP	NV\j[41EW0GQR1XS
HuO9	MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDmb2J4UUN3ME23Ok4xODR6IN88US=>	NEPFfHZUSU6JRWK=
CAL-51	NWPKSm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XY[GlEPTB;N{[uNVAxPiEQvF2=	M12we3NCVkeHUh?=
BT-20	NYGxSXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnNTWM2OD15Nj6yNVY5KM7:TR?=	MVnTRW5ITVJ?
LB831-BLC	NUCwRm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\vTHNnUUN3ME23Ok4{OjF5IN88US=>	NV\MVIU2W0GQR1XS
LB1047-RCC	MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHGNYpQUUN3ME23Ok44PjF7IN88US=>	MVfTRW5ITVJ?
ES8	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTd6LkCwO\|Mh\|ryP	MWXTRW5ITVJ?
UMC-11	M4LJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfWcIhYUUN3ME23PE4xQDh2IN88US=>	MlT4V2FPT0WU
NCI-H226	NWCyeYdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoW4TWM2OD15OD6xN\|E2KM7:TR?=	NG\qO2hUSU6JRWK=
IGROV-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTd6LkW1OUDPxE1?	M2LZVnNCVkeHUh?=
BHY	NFfU[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3lc2lKSzVyPUe5MlU6PiEQvF2=	NULRUnhqW0GQR1XS
MKN45	MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fmOGlEPTB;OECuN\|E4PCEQvF2=	NX7COmR7W0GQR1XS
IA-LM	NFPIWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjlWGRKSzVyPUiwMlM2OTFizszN	NGPGV4lUSU6JRWK=
WM-115	NYWxVpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRThzLkSxNVQh\|ryP	M2raV3NCVkeHUh?=
VMRC-RCZ	NVfFTXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmCzTWM2OD16MT60OFI2KM7:TR?=	MlPLV2FPT0WU
NCI-H2291	M{PaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XmSmlEPTB;OEGuOlg1OiEQvF2=	NGL0VZFUSU6JRWK=
MCF7	NYTyRYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2foWmlEPTB;OEOuNlg6PyEQvF2=	NH7pWXNUSU6JRWK=
639-V	M{PVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLmT3QzUUN3ME24OE43OTJ7IN88US=>	M2LnPXNCVkeHUh?=
RT4	MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjFO\|VpUUN3ME24OU4zPDB\|IN88US=>	M3PQe3NCVkeHUh?=
NCI-H2405	NH6wUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoewTWM2OD16NT6yPVk4KM7:TR?=	MVrTRW5ITVJ?
CAL-33	M4X2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4e3c2lEPTB;OEWuOlMyPSEQvF2=	NETodmxUSU6JRWK=
BT-549	NHuyTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrYPXVRUUN3ME24OU46Ozh{IN88US=>	MW\TRW5ITVJ?
HT-1197	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\LWZZKSzVyPUi4MlExPzdizszN	NH\tUIdUSU6JRWK=
G-361	NEDBOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXSTWM2OD16OD6xOFc1KM7:TR?=	M32xUXNCVkeHUh?=
LS-411N	M2n3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFWzVFRKSzVyPUi5MlM{QDhizszN	NEfNd3JUSU6JRWK=
HT-144	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7wVZJyUUN3ME24PU42QTl{IN88US=>	M1PqV3NCVkeHUh?=
DJM-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTh7Lki4OFUh\|ryP	M1XF[3NCVkeHUh?=
CAL-12T	NUi2fFdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHJXFlKSzVyPUmwMlc5QTVizszN	M4jXPXNCVkeHUh?=
MKN7	NFXrOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\NTWM2OD17MT6zOVUyKM7:TR?=	MYnTRW5ITVJ?
HuP-T3	M3rSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTl4LkGwNFQh\|ryP	MU\TRW5ITVJ?
SK-MG-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYT4No81UUN3ME25Ok4yOzR6IN88US=>	MWPTRW5ITVJ?
NCI-H2347	NUfMeHZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHwRXBYUUN3ME25PE4yODR{IN88US=>	NWLMSHlkW0GQR1XS
SW872	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDtRW5KSzVyPUGwNE41PTZizszN	MWPTRW5ITVJ?
COLO-829	NXLCeWtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULmfYhHUUN3ME2xNFAvPTV\|IN88US=>	MnOwV2FPT0WU
MC-IXC	NXvVOZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWH6[G4yUUN3ME2xNFAvPjF3IN88US=>	MmnzV2FPT0WU

... Click to View More Cell Line Experimental Data

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 9 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 9 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)